Shionogi Announces Acceptance of NDA for Naldemedine for the Treatment of Opioid-Induced Constipation

OSAKA, Japan and FLORHAM PARK, N.J., June 6, 2016 /PRNewswire/ -- Shionogi today announced that the New Drug Application (NDA) submitted in the U.S. for naldemedine, a once-daily, oral 0.2 mg tablet, has been accepted for review. In the U.S., the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news